Neuroprotective effect of rotigotine against complex i inhibitors, MPP + and rotenone, in primary mesencephalic cell culture

Folia Neuropathologica

Volumn 52, Issue 2, 2014, Pages 179-186

  Radad, Khaled ^a   Scheller, Dieter ^b   Rausch, Wolf Dieter ^c   Reichmann, Heinz ^d   Gille, Gabrielle ^d  

^a Assiut University   (Egypt)

^b UCB PHARMA   (Belgium)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Dopamine agonists; Dopaminergic neurons; Neuroprotection; Parkinson's disease; Rotenone; Rotigotine

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; NEUROPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; ROTENONE; ROTIGOTINE; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE; UNCOUPLING PROTEIN;

ANIMAL CELL; ARTICLE; BRAIN CELL CULTURE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EMBRYO; IMMUNOHISTOCHEMISTRY; MESENCEPHALIC CELL CULTURE; MESENCEPHALON; MOUSE; NEURITE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; ANIMAL; CELL CULTURE; DRUG EFFECTS; METABOLISM; NERVE CELL;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; CELLS, CULTURED; IMMUNOHISTOCHEMISTRY; MICE; NEURONS; NEUROPROTECTIVE AGENTS; REACTIVE OXYGEN SPECIES; ROTENONE; TETRAHYDRONAPHTHALENES; THIOPHENES; UNCOUPLING AGENTS;

EID: 84903598068     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: 10.5114/fn.2014.43789     Document Type: Article

References (34)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-458.
2. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000; 3: 1301-1306.
3. Birkmayer W, Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961. Wien Klin Wochenschr 2001; 113: 851-854.
4. Chen S, Zhang X, Yang D, Du Y, Li L, Li X, Ming M, Le W. D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase-and JNK-dependent pathways. FEBS Lett 2008; 582: 603-610.
5. Dhillon AS, Tarbutton GL, Levin JL, Plotkin GM, Lowry LK, Nalbone JT, Shepherd S. Pesticide/environmental exposures and Parkinson's disease in East Texas. J Agromedicine 2008; 13: 37-48.
6. Du F, Li R, Huang Y, Li X, Le W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci 2005; 22: 2422-2430.
7. Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W. Steadystate plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 2012; 34: 966-978.
8. Fernandez HH. Updates in the medical management of Parkinson disease. Cleve Clin J Med 2012; 79: 28-35.
9. Gille G, Radad K, Reichmann H, Rausch WD. Synergistic effect of alpha-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture. J Neural Transm 2006; 113: 1107-1118.
10. Gille G, Rausch WD, Hung ST, Moldzio R, Janetzky B, Hundemer HP, Kolter T, Reichmann H. Pergolide protects dopaminergic neurons in primary culture under stress conditions. J Neural Transm 2002; 109: 633-643.
11. Gille G, Rausch WD, Hung ST, Moldzio R, Ngyuen A, Janetzky B, Engfer A, Reichmann H. Protection of dopaminergic neurons in primary culture by lisuride. J Neural Transm 2002; 109: 157-169.
12. Gu M, Irvani M, Cooper JM, King D, Jenner P, Schapira AH. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem 2004; 91: 1075-1081.
13. Hurny A, Michałowska-Wender G, Wender M. Impact of L-DOPA treatment of patients with Parkinson's disease on mononuclear subsets and phagocytosis in the peripheral blood. Folia Neuropathol 2013; 51: 127-131.
14. Inden M, Kitamura Y, Tamaki A, Yanagida T, Shibaike T, Yamamoto A, Takata K, Yasui H, Taira T, Ariga H, Taniguchi T. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice. Neurochem Int 2009; 55: 760-767.
15. Keeney PM, Xie J, Capaldi RA, Bennett JP, Jr. Parkinson's disease brain mitochondrial complex I has oxidatively damaged sub units and is functionally impaired and misassembled. J Neurosci 2006; 26: 5256-5264.
16. Kitamura Y, Kohno Y, Nakazawa M, Nomura Y. Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice. Jpn J Pharmacol 1997; 74: 51-57.
17. Lipski J, Nistico R, Berretta N, Guatteo E, Bernardi G, Mercuri NB. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease? Prog Neurobiol 2011; 94: 389-407.
18. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 1989; 163: 1450-1455.
19. Muralikrishnan D, Mohanakumar KP. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998; 12: 905-912.
20. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 1985; 36: 2503-2508.
21. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 2000; 284: 1931-1938.
22. Pirtosek Z, Flisar D. Neuroprotection and dopamine agonists. Adv Exp Med Biol 2004; 541: 55-74.
23. Radad K, Moldzio R, Rausch WD. Minocycline protects dopaminergic neurons against long-term rotenone toxicity. Can J Neurol Sci 2010; 37: 81-85.
24. Radad K, Rausch WD, Gille G. Rotenone induces cell death in primary dopaminergic culture by increasing ROS production and inhibiting mitochondrial respiration. Neurochem Int 2006; 49: 379-386.
25. Richardson JR, Quan Y, Sherer TB, Greenamyre JT, Miller GW. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol Sci 2005; 88: 193-201.
26. Schapira AH. Dopamine agonists and neuroprotection in Parkinson's disease. Eur J Neurol 2002; 9 Suppl 3: 7-14.
27. Schapira AH. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 2009; 72: S44-S50.
28. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989; 333: 1269.
29. Scheller D, Chan P, Li Q, Wu T, Zhang R, Guan L, Ravenscroft P, Guigoni C, Crossman AR, Hill M, Bezard E. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp Neurol 2007; 203: 415-422.
30. Scheller D, Stichel-Gunkel C, Lubbert H, Porras G, Ravenscroft P, Hill M, Bezard E. Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease. Neurosci Lett 2008; 432: 30-34.
31. Scheller D, Ullmer C, Berkels R, Gwarek M, Lubbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 2009; 379: 73-86.
32. Sprenger F, Poewe W. Management of motor and non-motor symptoms in Parkinson's disease. CNS Drugs 2013; 27: 259-272.
33. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 2011; 119: 866-872.
34. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54: 93-101.